Global vaccine revenues will be $52bn (€36.2bn) in 2016, more than double the total for 2009, driven by new products and indication expansions of established therapies, according to a report.
New Jersey, US-based contractors Catalent Pharma Solutions and Compass Pharma Services expanded their respective blister pack offerings last week, both citing growing drug industry demand.
Latin America, new services and mid-sized pharma clients are targets for the incoming CEO of Clearstone Central Laboratories, who set out his vision for the business in an interview with Outsourcing-Pharma.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including Cel-Sci strengthening its manufacturing team and three promotions at Adolor.
SyberWorks is collaborating with the Validation and Compliance Institute (VCI) to provide FDA compliance training, including a programme covering cGMP production.
Lonza will shut down its API plant in Riverside, Pennsylvania, US by the end of the year as part of a plan to cut costs and shift small-molecule production to Asia.
Conducting trials in smaller patient populations when developing personalised medicines poses challenges, such as how to recruit patients fast enough, but these can be overcome using adaptive methods, according to a CEO.
The FDA has issued draft guidance detailing the information that should be submitted to an IRB as part of the continuing review of a clinical trial, with particular emphasis placed on the rise of multi-site studies.
Cambridge Consultants (CC) says experience developing auto-injector technologies was critical to its contract appraisal work during Consort Medical’s £16.8m (€11.5m) takeover of The Medical House (TMH).
Outsourcing-pharma presents a round up of all the latest deals and developments in the contract research space. This week Synexus closes ClinPharm deal, GVK joins ResearchPoint Global and CliniPace wins gNO contract.
Cel-Sci has completed validation of critical utilities and production equipment at its GMP facility which uses cold 4ºC aseptic filling to improve the shelf-life and potency and biologics.
Genzyme has reported a small dip in preliminary fourth quarter and full year revenues, driven by declining sales of Cerezyme and Fabrazyme which have been affected by manufacturing problems.
US CRO Charles River Laboratories (CRL) will halt operations at its preclinical services (PCS) facility in Massachusetts until demand for early-stage drug development recovers.
Continuing production of medically necessary products (MNPs) in the event of a pandemic will be made easier by developing a contingency plan, according to the FDA which has issued guidance on the subject.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including Genzyme strengthening its quality team and appointments at ISPE and Biogen Idec.
The SCDM says that edit checks are a crucial component of achieving error-free data and has updated its Good Clinical Data Management Practices (GCDMP) resource with a best practice guide.
US FDA has missed its review deadline for MannKind’s inhaled insulin candidate Afrezza after failing to complete inspection of third-party contract supplier.
European ScreeningPort is using IDBS’ ActivityBase XE to manage growing demand for screening services from the academic institutes which outsource to it.
US clinical trial review groups Independent Review Consulting (IRC) and Ethical Review Committee (ERC) are to merge and operate under the name Ethical and Independent Review Services (E&I).
A recently completed manufacturing and filling capacity expansion will help Florida Biologix meet deadlines and win repeat business according to company director Richard Snyder.
WuXi AppTec is partnering with Qiagen to develop biomarkers, assay panels and personalised healthcare diagnostics and will use these, and existing technologies, to further clients’ projects.
GSK says it will start making its BPH drug Avodart (dutasteride) at its facility in Poznan, Poland when it completes a PLN70m (€17m) capacity upgrade in January next year.
Vaccines could be produced in less than 10 weeks from first isolation of the RNA sequence by using insect cell derived influenza VLPs, according to research which has implications for H1N1 and H5N1.
Daiichi-Sankyo subsidiary Luitpold Pharmaceuticals has acquired PharmaForce, giving it a 40,000 sq ft cGMP compliant sterile manufacturing facility and a 20,000 sq ft API production plant.
The Hong Kong pharma sector should aim to adopt current World Health Organisation (WHO) GMP standards for drug manufacture within two years, according to a new report.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at DPT Laboratories, Datatrak and Dishman.
Piramal Healthcare is planning to raise Rs 10bn ($218m) over the next six to eight months to fund overseas acquisitions, with the India-based company eying several sectors including contract research.
Laureate Pharma and Selexis SA have entered into a joint-marketing relationship, drawing on their respective strengths in contract manufacturing and cell line development to shorten timelines.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including the retirement of Biogen Idec’s CEO and appointments at Dishman and Noven.
inVentiv Health claims the acquisition of ParagonRx positions it as the leading supplier of REMS services in the pharmaceutical contract services sector.
The US Department of Justice (DOJ) has given partial approval for Amcor’s takeover of Alcan after announcing it would now limit its review to Alcan’s Medical Flexible operations.
Ranbaxy Laboratories has sold its Chinese JV, Ranbaxy Guangzhou China Limited (RGCL), as part of a new approach to the country’s rapidly expanding drug market.
Zydus Cadila has become the first Indian pharma company to begin multi-centre clinical trials of a H1N1 vaccine after it received approval from the Drug Controller General of India (DCGI).
Genzyme is outsourcing fill and finish manufacturing of several major drugs to Hospira in response to in-house difficulties at its Allston Landing facility in Boston, Massachusetts, US.
Ownership of FrieslandCampina Domo’s pharmaceutical lactose business will be transferred to DMV-Fonterra Excipients, the 50/50 JV set up by Domo owner Royal FrieslandCampina and partner Fonterra.
The economic recovery will result in the resumption of delayed outsourcing deals and increased hiring but uncertainty remains and this could drive M&A, according to the IAOP which has listed 10 trends to watch in 2010.
McNeil Consumer Healthcare has recalled all lots of its Tylenol Arthritis Pain caplet 100 count bottles in the US due to reports of nausea and stomach pain.
